Licensing
← Earnings Calls
01
02
03
04 05 06
Tone
Capex
A1 A2 A3
CTVA
FY2025 Q4
Improving
Corteva, Inc. earnings call
Buzzberg read
Bayer resolution accelerates royalty neutrality to 2026
Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company.
Buzzberg read Bayer resolution accelerates royalty neutrality to 2026 Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company. Read full analysisCollapse analysis
Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company.
- Bayer settlement provides freedom to operate, accelerating corn licensing to 2027 and enabling US cotton licensing, with ~$1B EBITDA upside over 10 years.
- 2026 guidance: EBITDA midpoint $4.1B, EPS $3.45-$3.70, with expectations of 60% of sales and 85% of EBITDA in H1.
- Crop protection expects modest market growth in 2026 with volume growth in durables, but faces price pressure in Latin America and Asia Pacific.
Revenue$3.91BReported
EPS$0.22Reported
Gross margin42.35%Reported
Operating margin6.19%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Licensing
Bayer agreement to generate ~$1B EBITDA upside over 10 years
Licensing
Corn licensing accelerated to 2027, five years earlier
Show 3 more callouts
Innovation
Third-gen above-ground trait platform accelerated by two years
Demand
Crop protection market expected to grow modestly in 2026
Innovation
Gene-edited fungal disease resistant corn near commercialization
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $3.91B | Reported |
| EPS | $0.22 | Reported |
| Gross margin | 42.35% | Reported |
| Operating margin | 6.19% | Reported |
| Free cash flow | $4.153B | Reported |
| Capex | $0.222B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Operating margin | FY2026 | 22% | 22% | Guided |
AI, capex & demand read
Management read
Confident
Management expressed confidence in 2026 guidance, highlighted record performance, and emphasized accelerated opportunities from the Bayer resolution.
Investment and capacity
Management did not provide specific capital expenditure guidance, but mentioned ongoing asset and sourcing optimization in crop protection and investments in innovation, R&D at just over 8% of sales, and separation-related IT system separation costs.
all 1 named companies below
Companiesreturns since call
Partners
Partners
Chuck Magro
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years. — Opens new revenue streams for Corteva and potentially increases competitive pressure on Bayer's seed businesses.
Evidence
“We recently reached a comprehensive resolution with Bayer related to our seed, Freedom to Operate.”
External signals
Supply-chain alpha · 3returns since call
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years.
Evidence
“This resolution also facilitates the introduction of our third gen above ground trade platform in North America corn, which will be available for branded sales and licensing by the end of the decade.”
The 2026 tariff impact is $80M, mostly on crop protection from China-sourced active ingredients entering the US.
Evidence
“The estimate that we've got on the crop protection primarily is where the tariffs all are is encompassing everything we've got for the entire business... almost all of it is CP and almost all of it is China actives coming in to the United…”
Corteva expects to reach royalty neutrality in 2026, two years ahead of schedule, due to the Bayer settlement and licensing progress.
Evidence
“As a result of this resolution and the progress we've been making across the broader outlicensing spectrum, we now expect to achieve royalty neutrality in 2026, which is two years ahead of our most recent expectations.”
Methodology & coverage
Management-only analysis. All 1 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.